{
  "id": "589a246c78275d0c4a000032",
  "type": "list",
  "question": "Which 2 medications are included in the Qsymia pill?",
  "ideal_answer": "Qsymia pill includes phentermine and topiramate. It is used for treatment of obesity.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23590816",
    "http://www.ncbi.nlm.nih.gov/pubmed/23531960",
    "http://www.ncbi.nlm.nih.gov/pubmed/24222976",
    "http://www.ncbi.nlm.nih.gov/pubmed/23565717",
    "http://www.ncbi.nlm.nih.gov/pubmed/25826792",
    "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
    "http://www.ncbi.nlm.nih.gov/pubmed/23039320",
    "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
    "http://www.ncbi.nlm.nih.gov/pubmed/24991373",
    "http://www.ncbi.nlm.nih.gov/pubmed/23625271",
    "http://www.ncbi.nlm.nih.gov/pubmed/24986038"
  ],
  "snippets": [
    {
      "text": "OBJECTIVE: To quantify the incremental cost-effectiveness of Qsymia (phentermine and topiramate extended-release) for health-related quality of life improvements.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5\u00a0mg plus topiramate 46.0\u00a0mg) vs. control, which included diet and lifestyle advice plus placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include combinations (at low dose) of existing drugs, e.g., bupropion + naltrexone (Contrave), phentermine + topiramate (Qsymia), higher doses of existing drugs licensed for other indications (liraglutide, 3 mg), and new entities (lorcaserin).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia\u2122 and lorcaserin - Belviq\u00ae) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI \u2265 30 kg/m(2)) or in overweight persons (BMI \u2265 27 kg/m(2)) with comorbidities.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5\u00a0mg plus topiramate 46.0\u00a0mg) vs. control, which included diet and lifestyle advice plus placebo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Current antiobesity medications and pharmacological strategies will be reviewed.Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Almost a decade after the Food and Drug Administration approved the first weight loss medication, it recently approved two novel anti-obesity drugs Belviq (lorcaserin) and Qsymia (topiramate and phentermine), thus signalling the beginning of a new era in the pharmacotherapy of obesity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25826792",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Obesity is a public health crisis affecting approximately more than 33% of Americans and costing the healthcare system more than $190 billion annually.To review the 2 new drugs that were recently approved by the US Food and Drug Administration (FDA) for the treatment of obesity, lorcaserin HCl (Belviq) and phentermine/topiramate (Qsymia) and their potential impact on the treatment of obese patients.Lifestyle modification is the first and mainstay treatment for obesity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To review the 2 new drugs that were recently approved by the US Food and Drug Administration (FDA) for the treatment of obesity, lorcaserin HCl (Belviq) and phentermine/topiramate (Qsymia) and their potential impact on the treatment of obese patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991373",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "phentermine, topiramate"
}